Spots Global Cancer Trial Database for cancer vaccine
Every month we try and update this database with for cancer vaccine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 | NCT04534205 | Unresectable He... Metastatic Head... Recurrent Head ... | BNT113 Pembrolizumab | 18 Years - | BioNTech SE | |
| Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) | NCT03946358 | Squamous Cell C... Anal Canal Canc... Cervical Cancer | Blood sample co... Tumor biopsies CT scan Atezolizumab UCPVax | 18 Years - 75 Years | Centre Hospitalier Universitaire de Besancon | |
| Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer | NCT05794659 | Advanced Ovaria... | AST-201 Paclitaxel Carboplatin Placebo rhuGM-CSF(Granu... | 18 Years - | Aston Sci. Inc. | |
| Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer | NCT00389610 | Pancreatic Canc... | GVAX pancreas v... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal | NCT01341496 | Sarcoma Melanoma Epithelial Mali... Pleural Maligna... | Epigenetically ... Cyclophosphamid... Celecoxib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) | NCT03946358 | Squamous Cell C... Anal Canal Canc... Cervical Cancer | Blood sample co... Tumor biopsies CT scan Atezolizumab UCPVax | 18 Years - 75 Years | Centre Hospitalier Universitaire de Besancon | |
| Dendritic Cell Cancer Vaccine for High-grade Glioma | NCT01213407 | Glioblastoma Mu... | Trivax, Temozol... Temozolomide, S... | 3 Years - 70 Years | Activartis Biotech | |
| STRIDE - STimulating Immune Response In aDvanced brEast Cancer | NCT00925548 | Breast Cancer | Tecemotide (L-B... Placebo of tece... cyclophosphamid... sodium chloride... | 18 Years - | EMD Serono | |
| A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer | NCT04267237 | Non-small Cell ... | Atezolizumab RO7198457 | 18 Years - | Hoffmann-La Roche | |
| Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma | NCT00199901 | Melanoma | NY-ESO-1 ISCOMA... ISCOMATRIX® adj... | 18 Years - | Ludwig Institute for Cancer Research | |
| Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma | NCT01863108 | Melanoma Tumor Vaccines Effects of Immu... | GeniusVac-Mel4 | 18 Years - | University Hospital, Grenoble | |
| Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer | NCT06253494 | Endometrial Can... Cancer of Endom... Carcinoma of En... Endometrial Car... | AdHER2DC vaccin... Pembrolizumab N-803 Lenvatinib PATHWAY HER2 (4... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma | NCT01926639 | Follicular Lymp... | Radiotherapy, r... | 18 Years - | Oslo University Hospital | |
| A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer | NCT04267237 | Non-small Cell ... | Atezolizumab RO7198457 | 18 Years - | Hoffmann-La Roche | |
| A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer. | NCT00199836 | Cancer Neoplasm | NY-ESO-1b pepti... | 18 Years - | Ludwig Institute for Cancer Research | |
| PROvenge Treatment and Early Cancer Treatment | NCT00779402 | Prostate Cancer | Control Sipuleucel-T | 18 Years - 80 Years | Dendreon | |
| Neoantigen Derived DCs as Cancer Treatment | NCT05767684 | Refractory Tumo... Solid Tumor | Dendritic Cell ... Lenvatinib Nivolumab | 20 Years - | National Health Research Institutes, Taiwan | |
| Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal | NCT01341496 | Sarcoma Melanoma Epithelial Mali... Pleural Maligna... | Epigenetically ... Cyclophosphamid... Celecoxib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC) | NCT00089726 | Lung Cancer Carcinoma, Non-... | CG8123 Cyclophosphamid... | 18 Years - | Cell Genesys | |
| Comparison of the Human Papillomavirus (HPV) Type 16 E7-Specific Immune Response Between a Normal Population and Patients With Cervical Lesions | NCT00154583 | Cervical Cancer | 18 Years - 80 Years | National Taiwan University Hospital | ||
| Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma | NCT01290692 | Grade IV Glioma Grade IV Astroc... Glioblastoma Mu... | TVI-Brain-1 | 18 Years - | TVAX Biomedical | |
| Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma | NCT00199901 | Melanoma | NY-ESO-1 ISCOMA... ISCOMATRIX® adj... | 18 Years - | Ludwig Institute for Cancer Research | |
| AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer | NCT01741038 | Metastatic Colo... | AlloStim® cryoablation Physician's Cho... | 18 Years - | Immunovative Therapies, Ltd. | |
| Autologous TLPO Vaccine Basket | NCT06175221 | Tumor, Solid Tumor Metastasi... Cancer Tumor | Tumor lysate, p... | 18 Years - | Elios Therapeutics, LLC | |
| Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) | NCT01976520 | Chronic Lymphoc... | Oncoquest-CLL v... | 18 Years - | XEME Biopharma Inc. | |
| IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101) | NCT00785122 | Colorectal Carc... | Endoxana, Leuki... Endoxana, Leuki... | 18 Years - | Immatics Biotechnologies GmbH | |
| rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | NCT04943848 | Diffuse Intrins... Diffuse Midline... | rHSC-DIPGVax Balstilimab Zalifrelimab | 12 Months - 18 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | NCT01353222 | Urothelial Carc... | DN24-02 Standard of Car... | 18 Years - | Dendreon | |
| Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum | NCT02054104 | Thoracic Sarcom... Thorasic Cancer... Cancers of Non-... Sarcoma Melanoma | H1299 cell lysa... Cyclophosphamid... Celecoxib Iscomatrix adju... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer | NCT03908671 | Esophageal Canc... Non Small Cell ... | Personalized mR... | 18 Years - 75 Years | Stemirna Therapeutics | |
| Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme | NCT00323115 | Glioblastoma Mu... | Autologous Dend... Temozolomide Radiotherapy Dendritic Cell ... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L | NCT02232490 | Hepatocellular ... HCC Liver Cancer | hepcortespenlis... Placebo | 18 Years - | Immunitor LLC | |
| Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum | NCT01313429 | Sarcoma Melanoma Epithelial Mali... Pleural Maligna... | Cyclophosphamid... Allogenic tumor... Celecoxib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Study of a DNA Immunotherapy to Treat Melanoma | NCT01138410 | Malignant Melan... | SCIB1 | 18 Years - | Scancell Ltd | |
| Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00616941 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | NY-ESO-1 OLP4 NY-ESO-1 OLP4 +... NY-ESO-1 OLP4 +... | 18 Years - | Ludwig Institute for Cancer Research | |
| Vaccination With PD-L1 Peptide Against Multiple Myeloma | NCT03042793 | Multiple Myelom... | PD-L1 peptide v... | 18 Years - | Herlev Hospital | |
| The Role of B7-H4 in Tumor Vaccine | NCT06156150 | Glioma | tumor vaccine | 18 Years - 80 Years | Huashan Hospital | |
| QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer | NCT02751528 | Cancer | ETBX-021 | 18 Years - | NantBioScience, Inc. | |
| VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer | NCT01486329 | Stage IV Pancre... | VXM01 Placebo | 18 Years - | Vaximm GmbH | |
| Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. | NCT05243862 | Colorectal Canc... | PolyPEPI1018 Atezolizumab | 18 Years - | Treos Bio Limited | |
| VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer | NCT01486329 | Stage IV Pancre... | VXM01 Placebo | 18 Years - | Vaximm GmbH | |
| A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing | NCT00381173 | Breast Cancer Ovarian Cancer Prostate Cancer Colon Cancer Renal Cancer | Cyclophosphamid... | 18 Years - | Eisai Inc. | |
| Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma | NCT00518206 | Melanoma | NY-ESO-1 ISCOMA... Cyclophosphamid... | 18 Years - | Ludwig Institute for Cancer Research | |
| Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma | NCT01926639 | Follicular Lymp... | Radiotherapy, r... | 18 Years - | Oslo University Hospital | |
| Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer | NCT00648102 | Breast Cancer Colorectal Canc... Pancreatic Canc... Bladder Cancer Ovarian Cancer | CDX-1307 | 18 Years - | Celldex Therapeutics | |
| Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer | NCT00415818 | Carcinoma, Non-... | MVA-MUC1-IL2 1st line Chemot... | 18 Years - | Transgene | |
| Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ | NCT06218303 | Ductal Carcinom... | MUC1 Peptide Va... Hiltonol® Aromatase Inhib... | 18 Years - | University of Pittsburgh | |
| Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer | NCT05142189 | Non-Small Cell ... | BNT116 Cemiplimab Docetaxel Carboplatin Paclitaxel | 18 Years - | BioNTech SE | |
| QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer | NCT02751528 | Cancer | ETBX-021 | 18 Years - | NantBioScience, Inc. | |
| Sipuleucel-T Manufacturing Demonstration Study | NCT01477749 | Cancer of Prost... Cancer of the P... Neoplasms, Pros... Neoplasms, Pros... Prostate Cancer Prostate Neopla... Prostatic Cance... | sipuleucel-T | 18 Years - | Dendreon | |
| Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting | NCT02004262 | 2nd-line, 3rd-l... | GVAX Pancreas V... CRS-207 Chemotherapy cyclophosphamid... | 18 Years - | Aduro Biotech, Inc. | |
| Immunotherapy for Third Line Metastatic Colorectal Cancer | NCT04444622 | Metastatic Colo... | AlloStim | 18 Years - | Immunovative Therapies, Ltd. | |
| Dendritic Cell Based Therapy for Breast Cancer Patients | NCT00935558 | Breast Cancer | DC vaccine aromatase inhib... | 18 Years - | Herlev Hospital | |
| Phase II Trial of Allovectin-7® for Head and Neck Cancer | NCT00050388 | Head and Neck C... Squamous Cell C... Head and Neck N... Carcinoma of th... | Allovectin-7® | 18 Years - | Vical | |
| A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer | NCT00245362 | Metastatic Panc... Nonresectable P... | CG 8020 and CG ... | 18 Years - | Cell Genesys | |
| A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) | NCT05557591 | Advanced Non-Sm... | BNT116 Cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Vaccination With PD-L1 Peptide Against Multiple Myeloma | NCT03042793 | Multiple Myelom... | PD-L1 peptide v... | 18 Years - | Herlev Hospital | |
| Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG | NCT03879512 | Childhood Gliob... | depletion of re... reoperation cancer vaccine checkpoint bloc... | 3 Years - 21 Years | Wuerzburg University Hospital | |
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702) | NCT03520959 | Synovial Sarcom... Cancer Soft Tissue Sar... Sarcoma Metastatic Sarc... | LV305 G305 LV305-matching ... G305-matching p... | 12 Years - | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer | NCT02380443 | Colorectal Canc... | AlloStim Cryoablation | 18 Years - 80 Years | Immunovative Therapies, Ltd. | |
| Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas | NCT01143545 | Lung Cancer Esophageal Canc... Malignant Pleur... Sarcoma Thymic Carcinom... | Allogeneic Tumo... Celecoxib cyclophosphamid... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer | NCT05142189 | Non-Small Cell ... | BNT116 Cemiplimab Docetaxel Carboplatin Paclitaxel | 18 Years - | BioNTech SE | |
| Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer | NCT01431391 | Prostatic Neopl... Prostate Cancer Prostatic Adeno... | sipuleucel-T leuprolide acet... | 18 Years - | Dendreon | |
| IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101) | NCT00785122 | Colorectal Carc... | Endoxana, Leuki... Endoxana, Leuki... | 18 Years - | Immatics Biotechnologies GmbH | |
| Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer | NCT01592617 | Carcinoma, Non-... | S-488410 | 20 Years - 79 Years | Shiga University | |
| Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC | NCT04912765 | Hepatocellular ... Hepatocellular ... Colorectal Canc... Colorectal Carc... Liver Metastase... | Neoantigen Dend... Nivolumab | 21 Years - | National Cancer Centre, Singapore | |
| DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | NCT01353222 | Urothelial Carc... | DN24-02 Standard of Car... | 18 Years - | Dendreon | |
| AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer | NCT02380443 | Colorectal Canc... | AlloStim Cryoablation | 18 Years - 80 Years | Immunovative Therapies, Ltd. | |
| Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma | NCT00199901 | Melanoma | NY-ESO-1 ISCOMA... ISCOMATRIX® adj... | 18 Years - | Ludwig Institute for Cancer Research | |
| Combination Study of SV-BR-1-GM With Retifanlimab | NCT03328026 | Breast Cancer Breast Neoplasm Metastatic Brea... Breast Cancer M... | SV-BR-1-GM Low dose cyclop... Interferon Inoc... retifanlimab | 18 Years - | BriaCell Therapeutics Corporation | |
| DC Vaccine in Colorectal Cancer | NCT03730948 | Colorectal Canc... | DC vaccine | 18 Years - | University of Pennsylvania | |
| Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma | NCT01675765 | Malignant Pleur... | Immunotherapy p... Immunotherapy w... | 18 Years - | Aduro Biotech, Inc. | |
| Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum | NCT02054104 | Thoracic Sarcom... Thorasic Cancer... Cancers of Non-... Sarcoma Melanoma | H1299 cell lysa... Cyclophosphamid... Celecoxib Iscomatrix adju... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma | NCT04526899 | Melanoma Stage ... Melanoma Stage ... Unresectable Me... | BNT111 Cemiplimab | 18 Years - | BioNTech SE | |
| GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies | NCT00426205 | Myelodysplastic... Refractory Acut... Refractory CML ... | GM-CSF secretin... | 18 Years - | Dana-Farber Cancer Institute | |
| Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy | NCT00065442 | Prostate Cancer | Sipuleucel-T APC-Placebo | 18 Years - | Dendreon | |
| To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen | NCT00715078 | Prostate Cancer | sipuleucel-T | 18 Years - | Dendreon | |
| GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies | NCT00426205 | Myelodysplastic... Refractory Acut... Refractory CML ... | GM-CSF secretin... | 18 Years - | Dana-Farber Cancer Institute | |
| Sipuleucel-T Manufacturing Demonstration Study | NCT01477749 | Cancer of Prost... Cancer of the P... Neoplasms, Pros... Neoplasms, Pros... Prostate Cancer Prostate Neopla... Prostatic Cance... | sipuleucel-T | 18 Years - | Dendreon | |
| Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma | NCT00518206 | Melanoma | NY-ESO-1 ISCOMA... Cyclophosphamid... | 18 Years - | Ludwig Institute for Cancer Research |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
